Dec 31, 2021
Translational Science and Clinical Pharmacology CRO, Amador Bioscience, Announces the Completion of Over $60 Million in Series B+ Financing
The new round of financing was led by Heyu Capital (MSA), and the existing shareholders Sequoia China, Hillhouse Ventures, and Kaifeng Ventures.
\
The new round of financing was led by Heyu Capital (MSA), and the existing shareholders Sequoia China, Hillhouse Ventures, and Kaifeng Ventures. This is the second financing round that Amador has completed within a few months.
Entering a fast-paced development process
Following the completion of the B+ round of financing in September this year, the global development of Amador Bioscience has entered an accelerated stage: a branch in Shanghai is being set up and new laboratory facilities in California and Maryland -United States- are being built to expand the bioanalysis business. Besides this, a European subsidiary in Limburg, Belgium was set up last November.
At the same time, the company has cooperated with the University of Hasselt in Belgium to jointly build a clinical pharmacology postgraduate training program. Furthermore, Amador Bioscience acquired Ann Arbor Pharmacometrics Group (A2PG), a well-known quantitative pharmacology company in the United States, to deepen clinical pharmacology services and rapidly expand the professional team.
"Our vision is to become the preferred partner for the research and development of innovative drugs. We are committed to providing international standard translational science and clinical pharmacology services to biopharmaceutical companies in China, the United States, and Europe."
Dr. Bing Wang, Chairman and Chief Executive Officer.
“The company has been funded nearly $100 million from the B and B+ rounds of financing within just a few months, which would be similar to completing a key phase II trial node ( EOP2 ) in drug clinical development. We are very grateful for the trust of the investment institutions and the strong support of customers, employees, and partners.”
The lead investor of this round, Heyu Capital (MSA), is also a shareholder of the B round of financing. Zeng Yu, founding partner of Heyu Capital, said: “We are particularly optimistic about the overall technical level and execution of the team. Amador Bioscience is a pioneer in quantitative pharmacology”.
An outstanding CRO in the field of bioanalysis, with an increasing number of original innovative and first-in-class pharmaceutical projects in China, the unique technical capabilities of Amador will have more extensive value and market potential.
A company with an outstanding ability to expand its service capabilities and customer base through globalization is exactly the portrait of an innovative company preferred by us and Jade Capital. At the same time as the investment, Amador has realized the acquisition of A2PG in the United States, which is considered a beneficial internationalization step. We believe that this is just the beginning, and in the future, Dr. Bing Wang and his team are fully capable of taking this company to the next level.
“The results of this merger and acquisition continue to flourish. We look forward to a continuous improvement of its regional business coverage and the establishment of a more comprehensive service system to become a model for the internationalization of Chinese CRO companies.”
About MSA Capital
MSA Capital is a private equity investment institution with deep roots in China having a global perspective, focusing on early-stage and growth-stage investments in key areas such as healthcare, cutting-edge technology, Internet, and consumption.
Currently, MSA Capital has a management scale of over 1.7 billion USD. Headquartered in Beijing, it has resident teams in the United States, the Middle East, and Africa. With a broad global vision and profound international market insights, the team can help the invested companies quickly expand overseas markets based on local resources while exploring excellent investment opportunities.
